ReviewInternational journal of molecular sciences2025
Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Machine learning models based on MRI predict the expression levels of Galectin - 9 expression in rectal cancer.Abdominal radiology (New York) · 2026Article
- LGALS9 Is Beneficial to the Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation on Ischemic Stroke.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Decoding Galectin-Glycan Recognition withJournal of the American Chemical Society · 2026Article
- Single-cell profiling reveals peripheral blood immune landscape remodelling in breast cancer lymph node metastasis.Clinical and translational medicine · 2026Article
- LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.Journal for immunotherapy of cancer · 2026Article
- β-Mannosyl Triazoles as Mimics of Galactosyl Galectin-3 and Galectin-9 N-Terminal Domain Inhibitors.Chembiochem : a European journal of chemical biology · 2026Article
- TIM-3 in AML: pathogenic roles and therapeutic targetability.Clinical and experimental medicine · 2026Review
- PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression.Oncology research · 2026Article
- Platelet-Derived LGALS9 Suppresses NLRP3 Inflammasome-Dependent Pyroptosis in Pancreatic Acinar Cells During Severe Acute Pancreatitis.Journal of inflammation research · 2026Article
- Identification of immunosuppressive neutrophils using multi-omics: why functional testing remains key.Frontiers in immunology · 2026Review
- Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis.Biology · 2025Review
- The Neuro-Melanoma Singularity: Convergent Evolution of Neural and Melanocytic Networks in Brain Metastatic Adaptation.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Galectin-9 (Gal-9,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.